Different Rates of Bioprosthetic Aortic Valve Failure With Perimount™ and Trifecta™ Bioprostheses.

Front Cardiovasc Med · 2021 · PMC8811120 · PMID 35127875

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

just failed to reach significancep = 0.058so close (0.05 < p ≤ 0.1)

However, even in this subgroup, we found a clear tendency of higher redo rates in patients with Trifecta-composite grafts, which just failed to reach significance ( p = 0.058).

also in 279 other papers

did not reach statistical significancep = 0.133not close (p > 0.1)

a clear trendno p-value reported

A clear trend was identified with worse survival rates for the Trifecta group, which did not reach statistical significance: 79.5 ± 0.8% in the Perimount group and 68.1 ± 0.9% in the Trifecta group at 5 years and 76.1 ± 1.3% (PM group) and 63.7 ± 1.9% (TF Group) at 8 years ( p = 0.133, Figure 2 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.